Study on effect of psoralidin on anti-experimental postmenopausal osteoporosis and its mechanism.
- Author:
Jin-Ping LI
1
;
Xiao-Jing WANG
;
Ying ZENG
;
Qing LIN
;
Xin-Min MO
;
Shi-Jie LIU
;
Jun YANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Benzofurans; administration & dosage; Bone Density; drug effects; Coumarins; administration & dosage; Drugs, Chinese Herbal; administration & dosage; Estradiol; blood; Female; Humans; Osteoporosis, Postmenopausal; blood; drug therapy; physiopathology; Rats; Rats, Sprague-Dawley
- From: China Journal of Chinese Materia Medica 2013;38(11):1816-1819
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effect of psoralidine in rats with ovariectomy, and preliminarily study its mechanism.
METHODSixty female Sprague-Dawley rats were divided into 5 groups: the sham operation group, the model group, the psoralidine low-dose group (4 mg x kg(-1)), the psoralidine high-dose group (16 mg x kg(-1)) and the Zhuangguzhitong capsule group, with 12 rats in each group. Thirteen weeks later, their blood and bone samples were collected to detect bone density, bone biochemistry, pathomorphology, serum E2 and CT.
RESULTPsoralidine could up-regulate the bone density of lumbar vertebra and thighbone of rats with ovariectomy (P < 0.05), the maximum bending strength of thighbone (P < 0.05), and serum E2 and CT (P < 0.05).
CONCLUSIONPsoralidine has a good active effect on postmenopausal antiosteoporosis. Its mechanism may be related to such pathways as E2 and CT.
